<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220153</url>
  </required_header>
  <id_info>
    <org_study_id>UP0018</org_study_id>
    <secondary_id>2013-005469-38</secondary_id>
    <nct_id>NCT02220153</nct_id>
  </id_info>
  <brief_title>A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers</brief_title>
  <official_title>A Subject-Blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of UCB7665 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Celltech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and tolerability of single ascending doses of
      UCB7665 administered by intravenous or subcutaneous infusion in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events during the study</measure>
    <time_frame>Day -1 up to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>The value of the maximum plasma concentration will be directly obtained from the observed plasma concentration versus time curves. Pharmacokinetic samples will be taken predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to infinity (AUC)</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>AUC will be calculated using plasma concentrations taken at predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to time t, the time of last quantifiable concentration [AUC(0-t)]</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>AUC(0-t) will be calculated using plasma concentrations taken at predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>Tmax will be directly obtained from the observed plasma concentration versus time curves, using plasma concentrations taken at predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Immunoglobulin G (IgG ) concentrations</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>Total Immunoglobulin G will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G1 subclass concentrations</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G2 subclass concentrations</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G3 subclass concentrations</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G4 subclass concentrations</measure>
    <time_frame>Predose (Day 1) up to Day 85</time_frame>
    <description>Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>UCB7665 Intravenous 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose calculated based on body weight for 60 minutes intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB7665 Intravenous 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose calculated based on body weight for 60 minutes intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB7665 Intravenous 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose calculated based on body weight for 60 minutes intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB7665 Intravenous 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose calculated based on body weight for 60 minutes intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB7665 Intravenous 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose calculated based on body weight for 60 minutes intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB7665 Subcutaneous 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose calculated based on body weight for 60 minutes subcutaneous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB7665 Subcutaneous 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose calculated based on body weight for 60 minutes subcutaneous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose placebo comparator for each active arm of intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose placebo comparator for each active arm of subcutaneous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB7665 Intravenous 1</intervention_name>
    <description>Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion</description>
    <arm_group_label>UCB7665 Intravenous 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB7665 Intravenous 2</intervention_name>
    <description>Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion</description>
    <arm_group_label>UCB7665 Intravenous 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB7665 Intravenous 3</intervention_name>
    <description>Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion</description>
    <arm_group_label>UCB7665 Intravenous 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB7665 Intravenous 4</intervention_name>
    <description>Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion</description>
    <arm_group_label>UCB7665 Intravenous 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB7665 Intravenous 5</intervention_name>
    <description>Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion</description>
    <arm_group_label>UCB7665 Intravenous 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB7665 Subcutaneous 1</intervention_name>
    <description>Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: subcutaneous infusion</description>
    <arm_group_label>UCB7665 Subcutaneous 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCB7665 Subcutaneous 2</intervention_name>
    <description>Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: subcutaneous infusion</description>
    <arm_group_label>UCB7665 Subcutaneous 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous Placebo</intervention_name>
    <description>Active substance: Placebo
Pharmaceutical form: solution
Concentration: 0.9 % saline
Route of Administration: intravenous infusion</description>
    <arm_group_label>Intravenous Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Subcutaneous Placebo</intervention_name>
    <description>Active substance: Placebo
Pharmaceutical form: solution
Concentration: 0.9 % saline
Route of Administration: subcutaneous infusion</description>
    <arm_group_label>Subcutaneous Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers of non-childbearing potential who gave their
             consent to the written informed consent form

          -  Healthy volunteers in the age between 18 and 64 years old with normal weight as
             determined by a body mass index (BMI) between 18 and 30 kg/m^2, with a body weight of
             at least 50 kg for male subjects or 45 kg for female subjects

          -  Subjects has blood pressure (BP) and pulse within normal range in a supine position
             after 5 minutes rest

          -  Subject has clinical laboratory test results within the reference ranges of the
             testing laboratory or test results that are outside the specified ranges and that are
             deemed as clinically non-significant

          -  Subject's electrocardiogram (ECG) is considered &quot;normal&quot; or &quot;abnormal&quot; but clinically
             non-significant

        Exclusion Criteria:

          -  Subject has had significant blood loss, or has donated blood in excess of 400 mL of
             blood or blood products within 90 days before Day -2, or plans to donate blood during
             the clinical study

          -  Subject has a total Immuneglobulin G &lt;7 g/L or &gt;16 g/L at the Screening Visit

          -  Subject has absolute neutrophil count &lt;1.5x10^9/L and/or lymphocyte count &lt;1.0x10^9/L

          -  Subject has known viral hepatitis, has a positive test for Hepatitis B surface antigen
             or is Hepatitis C virus antibody positive

          -  Subject tests positive to Human Immunodeficiency Virus (HIV) 1/2 antibodies

          -  Subject has a past medical history or family history of primary immunodeficiency

          -  Subject is splenectomized

          -  Subject has a positive TIGRA (T cell interferon γ release assay) at the Screening
             Visit. If TIGRA is not available, purified protein derivative (PPD) skin test can be
             substituted and/or chest x-ray performed within 6 months before the Screening Visit
             showing no evidence of latent/active Tuberculosis (TB)

          -  Subject has past (in the last 12 months ) or present substance abuse/dependence or
             concurrent medical conditions that in the opinion of the investigator could confound
             clinical study interpretation or affect the subject's ability to fully participate in
             the clinical study

          -  Subject has a known hypersensitivity to any components of the Investigational
             Medicinal Product (IMP)

          -  Subject has an active infection or has had a serious infection (resulting in
             hospitalization or requiring parenteral antibiotic treatment) within 6 weeks before
             the first dose of IMP

          -  Subject has 12-lead electrocardiogram (ECG) with changes considered to be clinically
             significant upon medical review

          -  Subject has renal impairment

          -  Subject has hepatic impairment

          -  Subject has corrected serum calcium of &gt;11.5 mg/dL (&gt;2.9 mmol/L) or &lt;8.0 mg/dL (&lt;2.0
             mmol/L) at the Screening Visit

          -  Subject has active neoplastic disease or history of neoplastic disease within 5 years
             of entry in the clinical study

          -  Subject has any other acute or chronic illness which, in the opinion of the
             investigator or study physician, could pose a threat or harm to the subjects

          -  Subject has received a vaccination within 6 weeks before the Screening Visit or
             intends to have a vaccination before Day 43 of the Safety Follow-up Period

          -  Subject has received any IMP or experimental procedure within 90 days before the first
             dose of IMP

          -  Subject requires a treatment other than Paracetamol during the clinical study

          -  Subject is a vulnerable subject (e.g. subject kept in detention) (Declaration of
             Helsinki, 1996)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>001</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>October 2, 2015</last_update_submitted>
  <last_update_submitted_qc>October 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monoclonal antibody</keyword>
  <keyword>subjects</keyword>
  <keyword>First in human</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

